Article

FDA Advises Against High-Dose Acetaminophen Combinations

The Food and Drug Administration has advised physicians to discontinue prescribing medications that contain more than 325 mg per dose of acetaminophen, citing risks to the liver.

The Food and Drug Administration has advised physicians to discontinue prescribing medications that contain more than 325 mg per dose of acetaminophen, citing risks to the liver.

There is no good evidence for efficacy above this dose, says the Safety Alert from the Agency, and severe liver injury has occurred in patients who took more than the recommended dose over 24 hours, combined different drugs containing acetaminophen, or drank alcohol while taking the drug.

Although manufacturers of over-the-counter drugs have limited acetaminophen doses to 325 mg, some prescription combinations continue to contain larger doses. The FDA says it is considering withdrawing approval for these combinations.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
© 2025 MJH Life Sciences

All rights reserved.